| Hearing loss | Age years | Tinnitus | Maximal hearing loss# dB | Frequencies¶ n (NCI CTCAE grade) | Stopped amikacin early (reason) | Progression of hearing loss after amikacin cessation? | Total treatment period days | Total dose g |
| Gradable hearing loss | 29 | Yes | 50 | 2 (2) | Yes (hearing loss) | Yes | 139 | 104.3 |
| 26 | Yes | 75 | 6 (3) | Yes (hearing loss) | Yes | 160 | 160 | |
| 37 | No | 55 | 1 (2) | Yes (hearing loss) | No | 91 | 81.9 | |
| 23 | No | 75 | 4 (3) | Yes (hearing loss) | Yes | 125 | 87.5 | |
| Early non-gradable hearing loss | 31 | No | 15 | 1 (-) | Yes (hearing loss) | Unknown | 75 | 75 |
| 26 | No | 15 | 1 (-) | Yes (hearing loss) | No | 123 | 115 | |
| 42 | No | 25 | 1 (-) | Yes (hearing loss) | No | 178 | 109.9 | |
| No hearing loss | 28 | Yes | 20 | 1 (-) | Yes (tinnitus) | No | 119 | 107 |
| 20 | No | 10 | 0 (-) | Yes (eczematous drug reaction+) | No | 121 | 77.5 | |
| 19 | No | 5 | 0 (-) | Yes (morning fatigue§) | Unknown | 78 | 54.6 | |
| 50 | No | 0 | 0 (-) | No | Unknown | 92 | 92 | |
| 24 | No | 10 | 0 (-) | No | No | 180 | 119.4 |
“Gradable hearing loss” indicates pure tone audiogram changes sufficient to be categorised as grade 1 hearing loss (loss of 15–25 dB averaged at two or more contiguous frequencies in at least one ear) or higher. “Early non-gradable hearing loss” indicates audiogram changes insufficient to be gradable, but of clinical concern. Tinnitus self-reported by patients. #: from baseline at 8000 Hz; ¶: at which sustained loss ≥15 dB detected, with National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) grade allocated in parentheses; +:adverse event immediately following i.v. injection of amikacin; §: distressing morning fatigue resolving only after discontinuation of amikacin.